Neuronetics Inc STIM.OQ STIM.O is expected to show a fall in quarterly revenue when it reports results on February 17 (estimated) for the period ending December 31 2024
The Malvern Pennsylvania-based company is expected to report a 3.3% decrease in revenue to $19.634 million from $20.31 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.The company's guidance on November 12 2024, for the period ended December 31, was for revenue between $19.00 million and $20.00 million.
LSEG's mean analyst estimate for Neuronetics Inc is for a loss of 25 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Neuronetics Inc is $3.00, below its last closing price of $3.90.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.23 | -0.23 | -0.44 | Missed | -91.3 |
Jun. 30 2024 | -0.27 | -0.27 | -0.33 | Missed | -22.2 |
Mar. 31 2024 | -0.32 | -0.31 | -0.27 | Beat | 12.9 |
Dec. 31 2023 | -0.26 | -0.26 | -0.19 | Beat | 27.3 |
Sep. 30 2023 | -0.31 | -0.31 | -0.33 | Missed | -6.7 |
Jun. 30 2023 | -0.35 | -0.35 | -0.17 | Beat | 51.2 |
Mar. 31 2023 | -0.39 | -0.39 | -0.38 | Beat | 2.1 |
Dec. 31 2022 | -0.35 | -0.38 | -0.30 | Beat | 21.3 |
This summary was machine generated February 14 at 13:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。